Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2009 Jan;8(1):51-66. doi: 10.1586/14760584.8.1.51.

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.

Author information

1
Tumor Immunology Program, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. p.fournier@dkfz-heidelberg.de

Abstract

This review elucidates state-of-the-art clinical studies on active specific immunotherapy with tumor vaccines. It refers solely to randomized studies and has a special focus on patient's survival, the most important parameter for any therapy. Of special interest, from a tumor immunological point of view, is a comparison between the results obtained with allogeneic tumor cell-derived vaccines and those obtained with autologous tumor cell-derived vaccines. Overall, autologous vaccines have given better results than allogeneic vaccines. Random mutations in cancer generate unique antigens in each individual case. The superiority of autologous vaccines suggests that unique tumor-associated antigens are particularly important in generating responsive T cells for a therapeutic effect.

PMID:
19093773
DOI:
10.1586/14760584.8.1.51
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center